Smith Colette J, Sabin Caroline A, Youle Mike S, Kinloch-de Loes Sabine, Lampe Fiona C, Madge Sara, Cropley Ian, Johnson Margaret A, Phillips Andrew N
Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom.
J Infect Dis. 2004 Nov 15;190(10):1860-8. doi: 10.1086/425075. Epub 2004 Oct 8.
Highly active antiretroviral therapy (HAART) results in an improvement in immunologic function. We sought to investigate the factors associated with increases in CD4 cell count among human immunodeficiency virus (HIV)-positive antiretroviral-naive patients starting HAART.
Five hundred ninety-six subjects were followed for a median of 2.5 years (interquartile range, 1.0-4.0 years). Factors associated with changes in CD4 cell counts in the first 3 months of HAART and from 3 months onwards were analyzed.
After 6, 12, and 24 months of HAART, the median increases in CD4 cell counts were 114, 181, and 248 cells/mm3, respectively; 84%, 84%, and 80% of subjects had a virus load of <400 copies/mL during the same periods. White ethnicity, higher pre-HAART virus load, and lower pre-HAART CD4 and CD8 cell counts were associated with greater increases in CD4 cell counts during the first 3 months of HAART. From 3 months onward, a greater cumulative proportion of time spent with virus load <400 copies/mL was associated with a more favorable change in CD4 cell count (an average increase of 5.2 cells/mm3/year [95% confidence interval [CI], 3.8-6.7 cells/mm3/year] for each extra 10% cumulative time spent with a virus load <400 copies/mL) (P<.0001). For every 100 cells/mm3 higher in baseline CD4 cell count, the increase was 6 cells/mm3/year less (95% CI, 2-11 cells/mm3/year) (P=.02). Sex, risk group, age, and HAART regimen were not associated with increases in CD4 cell counts.
These findings emphasize the importance of maintaining virological suppression and suggest other factors that influence long-term CD4 cell response.
高效抗逆转录病毒疗法(HAART)可改善免疫功能。我们试图调查开始接受HAART治疗的未接受过抗逆转录病毒治疗的人类免疫缺陷病毒(HIV)阳性患者中,与CD4细胞计数增加相关的因素。
对596名受试者进行了为期2.5年的随访(四分位间距为1.0 - 4.0年)。分析了与HAART治疗前3个月及3个月后CD4细胞计数变化相关的因素。
HAART治疗6个月、12个月和24个月后,CD4细胞计数的中位数增加分别为114、181和248个细胞/mm³;同期分别有84%、84%和80%的受试者病毒载量<400拷贝/mL。白人种族、HAART治疗前较高的病毒载量以及HAART治疗前较低的CD4和CD8细胞计数与HAART治疗前3个月CD4细胞计数的更大增加相关。从3个月起,病毒载量<400拷贝/mL的累积时间比例越高,与CD4细胞计数的更有利变化相关(每额外10%的病毒载量<400拷贝/mL的累积时间,平均增加5.2个细胞/mm³/年[95%置信区间(CI),3.8 - 6.7个细胞/mm³/年])(P<0.0001)。基线CD4细胞计数每高100个细胞/mm³,增加量每年减少6个细胞/mm³(95%CI,2 - 11个细胞/mm³/年)(P = 0.02)。性别、风险组、年龄和HAART治疗方案与CD4细胞计数增加无关。
这些发现强调了维持病毒学抑制的重要性,并提示了影响长期CD4细胞反应的其他因素。